Byol Shin, DO
Allergy & Immunology · Lawrenceville, GANPI 1669680401
Payments from drug & device makers
Across 547 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- Optinose US, Inc.$1K
- GSK$1K
- AbbVie$966
- Amgen$850
- plus $5K from 34 others
What the payments were for
- Consulting fees$8927%
- Speaking & faculty fees$3503%
- Food & beverage$10,43987%
- Education$2942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 46 | $1,523 |
| AstraZeneca | 74 | $1,505 |
| Optinose US, Inc. | 18 | $1,091 |
| GSK | 56 | $1,041 |
| AbbVie | 67 | $966 |
| Amgen | 51 | $850 |
| Regeneron Healthcare Solutions, Inc. | 30 | $719 |
| CSL Behring | 26 | $505 |
| Grifols USA, LLC | 17 | $305 |
| Novartis | 15 | $302 |
| Mylan Specialty L.p. | 16 | $300 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $289 |
| Pfizer | 11 | $259 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $257 |
| Sanofi-aventis U.S. LLC | 3 | $215 |
| Biocryst US Sales Co., LLC | 11 | $213 |
| Octapharma USA, Inc. | 5 | $192 |
| Incyte Corporation | 11 | $188 |
| Boehringer Ingelheim | 10 | $176 |
| Galderma Laboratories, L.p. | 7 | $115 |
| Genentech USA, Inc. | 5 | $102 |
| LEO Pharma Inc. | 5 | $95 |
| Ionis Pharmaceuticals, Inc. | 4 | $90 |
| Kaleo, Inc. | 6 | $86 |
| Novo Nordisk | 1 | $82 |
| Azurity Pharmaceuticals, Inc. | 4 | $76 |
| Organon | 4 | $59 |
| Phadia US Inc. | 3 | $55 |
| Lilly USA, LLC | 2 | $49 |
| ADMA Biomanufacturing LLC | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Upsher-smith Laboratories LLC | 2 | $28 |
| Blueprint Medicines Corporation | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Viatris Specialty LLC | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Alk-abello, Inc | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,975 in reported general payments places this provider in the 65th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 43 | $158,668 |
| Dupixent SyringeDupilumab | 32 | $118,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $43,013 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $18,036 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $6,413 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,496 |
| Ipratropium Bromide | 51 | $1,591 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,073 |
| Fluticasone Propionate | 78 | $859 |
| Azelastine Hcl | 41 | $832 |
| Triamcinolone Acetonide | 44 | $487 |
| Montelukast Sodium | 51 | $451 |
| Levocetirizine Dihydrochloride | 18 | $209 |
| Famotidine | 19 | $109 |
| Azithromycin | 16 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,041 | $61,04991 claims |
| AstraZenecaSymbicort | $1,505 | $6,41328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Lawrenceville
- Poneh HeineLawrenceville$14K
- Jon StahlmanLawrenceville$10K
- Syeda HamadaniLawrenceville$6K
- Nathan SegallStockbridge$4.5M
- Tracy BridgesAlbany$1.5M
- Brad GoodmanSavannah$1.3M
- Michael BlaissRoswell$1.1M
- Robert ChrzanowskiColumbus$941K
- Stanley FinemanMarietta$855K
- Robert CartwrightColumbus$678K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.